Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients

[1]  Delila Gasi Tandefelt,et al.  Plasma AR and abiraterone-resistant prostate cancer , 2015, Science Translational Medicine.

[2]  P. Rennie,et al.  Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. , 2015, The Journal of Biological Chemistry.

[3]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[4]  Dustin R. Bunch,et al.  Conversion of abiraterone to D4A drives antitumor activity in prostate cancer , 2015, Nature.

[5]  Martin E. Gleave,et al.  Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer , 2015, Clinical Cancer Research.

[6]  A. Zoubeidi,et al.  Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer. , 2014, Chemistry & biology.

[7]  M. Gleave,et al.  Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer , 2014, Molecular Cancer Therapeutics.

[8]  M. Loda,et al.  Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors , 2014, Clinical Cancer Research.

[9]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[10]  P. Rennie,et al.  Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3). , 2014, Journal of medicinal chemistry.

[11]  Myles A Brown,et al.  Coregulator Control of Androgen Receptor Action by a Novel Nuclear Receptor-binding Motif* , 2014, The Journal of Biological Chemistry.

[12]  Gang Shao,et al.  A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. , 2013, Cancer discovery.

[13]  Joshua M. Korn,et al.  An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). , 2013, Cancer discovery.

[14]  P. Rennie,et al.  Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer , 2013, International journal of molecular sciences.

[15]  V. Arora,et al.  Overcoming mutation-based resistance to antiandrogens with rational drug design , 2013, eLife.

[16]  O. Sartor,et al.  Enzalutamide for the treatment of prostate cancer , 2013, Expert opinion on pharmacotherapy.

[17]  Artem Cherkasov,et al.  Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives. , 2013, Journal of medicinal chemistry.

[18]  J. Hoffman-Censits,et al.  Enzalutamide: A Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer , 2013, Clinical Cancer Research.

[19]  N. Vogelzang.  Enzalutamide--a major advance in the treatment of metastatic prostate cancer. , 2012, The New England journal of medicine.

[20]  Tapio Visakorpi,et al.  Androgen receptor (AR) aberrations in castration-resistant prostate cancer , 2012, Molecular and Cellular Endocrinology.

[21]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[22]  H. Scher,et al.  ARN-509: a novel antiandrogen for prostate cancer treatment. , 2012, Cancer research.

[23]  Artem Cherkasov,et al.  Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening. , 2011, Journal of medicinal chemistry.

[24]  D. Tindall,et al.  Alternatively spliced androgen receptor variants. , 2011, Endocrine-related cancer.

[25]  R. Fletterick,et al.  Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells , 2011, Proceedings of the National Academy of Sciences.

[26]  Klaus Pantel,et al.  Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.

[27]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[28]  N. Socci,et al.  Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor , 2010, Proceedings of the National Academy of Sciences.

[29]  J. Humm,et al.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.

[30]  Guido Jenster,et al.  Systematic Structure-Function Analysis of Androgen Receptor Leu701 Mutants Explains the Properties of the Prostate Cancer Mutant L701H* , 2009, The Journal of Biological Chemistry.

[31]  K. Pantel,et al.  Cell-free Tumor DNA in Blood Plasma As a Marker for Circulating Tumor Cells in Prostate Cancer , 2009, Clinical Cancer Research.

[32]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[33]  Phuong Nguyen,et al.  A surface on the androgen receptor that allosterically regulates coactivator binding , 2007, Proceedings of the National Academy of Sciences.

[34]  Vishnu Swarup,et al.  Circulating (cell‐free) nucleic acids – A promising, non‐invasive tool for early detection of several human diseases , 2007, FEBS letters.

[35]  D. Jacqmin,et al.  Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer , 2006, Cellular and Molecular Life Sciences CMLS.

[36]  I. McEwan,et al.  Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions. , 2005, Molecular endocrinology.

[37]  Duane D. Miller,et al.  Structural Basis for Accommodation of Nonsteroidal Ligands in the Androgen Receptor* , 2005, Journal of Biological Chemistry.

[38]  H. Scher,et al.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Dalton,et al.  Chemistry and structural biology of androgen receptor. , 2005, Chemical reviews.

[40]  Duane D. Miller,et al.  Structural basis for antagonism and resistance of bicalutamide in prostate cancer , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Bin He,et al.  Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. , 2004, Molecular cell.

[42]  Desok Kim,et al.  The Androgen Axis in Recurrent Prostate Cancer , 2004, Clinical Cancer Research.

[43]  P. Kantoff,et al.  Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Donna M. Peehl,et al.  Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor , 2000, Nature Medicine.

[45]  E. Small,et al.  Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. , 1999, Cancer research.

[46]  G. Bubley,et al.  Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[48]  H. Klocker,et al.  Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. , 1993, Molecular endocrinology.

[49]  N. Sato,et al.  Androgen receptor gene mutations in human prostate cancer , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[50]  W. Isaacs,et al.  Androgen receptor gene mutations in human prostate cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[51]  T. H. van der Kwast,et al.  Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. , 1991, Molecular endocrinology.

[52]  G. Jenster,et al.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.

[53]  J. Bono,et al.  Switching and withdrawing hormonal agents for castration-resistant prostate cancer , 2015, Nature Reviews Urology.

[54]  Hideo Araki,et al.  Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. , 2003, Cancer research.

[55]  D. Peehl,et al.  Erratum: Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor (Nature Medicine (2000) 6 (703-706)) , 2000 .

[56]  L. Denis,et al.  Pharmacodynamics and pharmacokinetics of bicalutamide: defining an active dosing regimen. , 1996, Urology.